Boustani M, Campbell N, Munger S, Maidment I, Fox C. Impact of anticholinergics on the aging brain: a review and practical application. Aging Health
2008; 4: 311–20.
Smithard DG, Fox C, Maidment ID, Katona C, Boustani M. Do anticholinergic drugs contribute to functional and cognitive decline?
2012; 8: 57–60.
Campbell N, Boustani M, Limbil T, Ott C, Fox C, Maidment I, et al. The cognitive impact of anticholinergics: a clinical review. Clin Interv Aging
2009; 4: 225.
Flacker JM, Cummings V, Mach JR Jr, Bettin K, Kiely DK, Wei J. The association of serum anticholinergic activity with delirium in elderly medical patients. Am J Geriatr Psychiatry
1999; 6: 31–41.
O'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing
2015; 44: 213–8.
Ruxton K, Woodman RJ, Mangoni AA. Drugs with anticholinergic effects and cognitive impairment, falls and all-cause mortality in older adults: a systematic review and meta-analysis. Br J Clin Pharmacol
2015; 80: 209–20.
Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA
2015; 175: 401–7.
Heslop P, Blair PS, Fleming P, Hoghton M, Marriott A, Russ L. The Confidential Inquiry into premature deaths of people with intellectual disabilities in the UK: a population-based study. Lancet
2014; 383: 889–95.
Buszewicz M, Welch C, Horsfall L, Nazareth I, Osborn D, Hassiotis A, et al. Assessment of an incentivised scheme to provide annual health checks in primary care for adults with intellectual disability: a longitudinal cohort study. Lancet Psychiatry
2014; 1: 522–30.
Haveman M, Heller T, Lee L, Maaskant M, Shooshtari S, Strydom A. Major health risks in aging persons with intellectual disabilities: an overview of recent studies. J Policy Pract Intellect Disabil
2010; 7: 59–69.
Haveman M, Perry J, Salvador-Carulla L, Walsh PN, Kerr M, Van Schrojenstein LV, et al. Ageing and health status in adults with intellectual disabilities: results of the European POMONA II study. J Intellect Dev Disabil
2011; 36: 49–60.
McCarron M, O'Dwyer M, Burke E, McGlinchey E, McCallion P. Epidemiology of epilepsy in older adults with an intellectual disability in Ireland: associations and service implications. Am J Intellect Dev Disabil
2014; 119: 253–60.
Cooper S-A, Smiley E, Morrison J, Williamson A, Allan L. Mental ill-health in adults with intellectual disabilities: prevalence and associated factors. Br J Psychiatry
2007; 190: 27–35.
Tyrer P, Cooper S-A, Hassiotis A. Drug treatments in people with intellectual disability and challenging behaviour. BMJ
2014; 349: g4323.
National Audit Office. Care Services for People with Learning Disabilities and Challenging Behaviour: Report by the Comptroller and Auditor General. National Audit Office, 2015.
Department of Health. Transforming Care: A National Response to Winterbourne View Hospital. Department of Health Review Final Report. Department of Health, 2012.
Bhaumik S, Branford D. The Frith Prescribing Guidelines for Adults with Learning Disability: United Kingdom. Taylor and Francis, 2005.
Han L, Agostini JV, Allore HG. Cumulative anticholinergic exposure is associated with poor memory and executive function in older men. J Am Geriatr Soc
2008; 56: 2203–10.
Mintzer J, Burns A. Anticholinergic side-effects of drugs in elderly people. J Roy Soc Med
2000; 93: 457.
Fox C, Richardson K, Maidment ID, Savva GM, Matthews FE, Smithard D, et al. Anticholinergic medication use and cognitive impairment in the older population: the Medical Research Council Cognitive Function and Ageing study. J Am Geriatr Soc
2011; 59: 1477–83.
Salahudeen MS, Hilmer SN, Nishtala PS. Comparison of anticholinergic risk scales and associations with adverse health outcomes in older people. J Am Geriatr Soc
2015; 63: 85–90.
McCarron M, Swinburne J, Burke E, McGlinchey E, Mulryan N, Andrews V, et al. Growing Older with an Intellectual Disability in Ireland 2011: First Results from the Intellectual Disability Supplement of The Irish Longitudinal Study on Ageing School of Nursing. School of Midwifery and Nursing, Trinity College Dublin, 2011.
McCarron M, Swinburne J, Burke E, McGlinchey E, Carroll R, McCallion P. Patterns of multimorbidity in an older population of persons with an intellectual disability: results from the intellectual disability supplement to the Irish longitudinal study on aging (IDS-TILDA). Res Dev Disabil
2013; 34: 521–7.
Janicki MP, Dalton AJ. Dementia and Aging Adults with Intellectual Disabilities: A Handbook. Routledge, 2014.
Lavin KE, McGuire BE, Hogan MJ. Age at death of people with an intellectual disability in Ireland. J Intellect Disabil
2006; 10: 155–64.
Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): Explanation and elaboration. Int J Surg
2014; 12: 1500–24.
World Health Organization. Anatomical Chemical Therapeutic Classification System. WHO, 2011.
Mac Giolla Phadraig C, McCallion P, Cleary E, McGlinchey E, Burke E, McCarron M, et al. Total tooth loss and complete denture use in older adults with intellectual disabilities in Ireland. J Public Health Dent
2014; 75: 101–8.
Tabachnick B, Fidell LS. Using Multivariate Statistics (6th edn). Pearson, 2013.
Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol
1996; 49: 1373–9.
Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc Series B Stat Methodol
1995; 57: 289–300.
Myint PK, Fox C, Kwok CS, Luben RN, Wareham NJ, Khaw K-T. Total anticholinergic burden and risk of mortality and cardiovascular disease over 10 years in 21,636 middle-aged and older men and women of EPIC-Norfolk prospective population study. Age Ageing
2014: 44: 219–25.
Richardson K, Bennett K, Maidment ID, Fox C, Smithard D, Kenny RA. Use of medications with anticholinergic activity and self-reported injurious falls in older community-dwelling adults. J Am Geriatr Soc
2015; 63: 1561–9.
Tsiouris JA, Kim S-Y, Brown WT, Pettinger J, Cohen IL. Prevalence of psychotropic drug use in adults with intellectual disability: positive and negative findings from a large scale study. J Autism Dev Disord
2013: 43: 732.
Stolker JJ, Heerdink ER, Leufkens HG, Clerkx MG, Nolen WA. Determinants of multiple psychotropic drug use in patients with mild intellectual disabilities or borderline intellectual functioning and psychiatric or behavioral disorders. Gen Hosp Psychiatry
2001; 23: 345–9.
Haider SI, Ansari Z, Vaughan L, Matters H, Emerson E. Prevalence and factors associated with polypharmacy in Victorian adults with intellectual disability. Res Dev Disabil
2014; 35: 3071–80.
Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA
2008; 300: 2867–78.
Paton C, Flynn A, Shingleton-Smith A, McIntyre S, Bhaumik S, Rasmussen J, et al. Nature and quality of antipsychotic prescribing practice in UK psychiatry of intellectual disability services. J Intellect Disabil Res
2011; 55: 665–74.
Banerjee S. The Use of Antipsychotic Medication for People with Dementia: Time for Action. Department of Health, 2009.
Taylor D, Paton C, Kapur S. The Maudsley Prescribing Guidelines in Psychiatry. John Wiley & Sons, 2015.
Lu W-H, Wen Y-W, Chen L-K, Hsiao F-Y. Effect of polypharmacy, potentially inappropriate medications and anticholinergic burden on clinical outcomes: a retrospective cohort study. CAMJ
2015; 187: E130–7.
Gallagher P, O'Mahony D. Constipation in old age. Best Pract Res Clin Gastroenterol
2009; 23: 875–87.
Böhmer C, Taminiau J, Klinkenberg-Knol E, Meuwissen S. The prevalence of constipation in institutionalized people with intellectual disability. J Intellect Disabil Res
2001; 45: 212–8.
Gil-Montoya JA, de Mello ALF, Barrios R, Gonzalez-Moles MA, Bravo M. Oral health in the elderly patient and its impact on general well-being: a nonsystematic review. Clin Interv Aging
2015; 10: 46.
Gøtzsche PC, Young AH, Crace J. Does long term use of psychiatric drugs cause more harm than good?
2015; 350: h2435.
Gerretsen P, Pollock BG. Drugs with anticholinergic properties: a current perspective on use and safety. Exp Opin Drug Safety
2011; 10: 751–65.
Oliver D. Guest editorial: Integrated services for older people – the key to unlock our health and care services and improve the quality of care?
J Res Nurs
2015; 20: 5–11.
Maidment ID, Haw C, Stubbs J, Fox C, Katona C, Franklin BD. Medication errors in older people with mental health problems: a review. Int J Geriatr Psychiatry
2008; 23: 564–73.
McCartney M. Drugs with anticholinergic side effects and cognitive decline – cause or effect?
2015; 350: h1428.
Freedman RI. Ethical challenges in the conduct of research involving persons with mental retardation. Mental Retard
2001; 39: 130–41.
Chew ML, Mulsant BH, Pollock BG, Lehman ME, Greenspan A, Mahmoud RA, et al. Anticholinergic activity of 107 medications commonly used by older adults. J Am Geriatr Soc
2008; 56: 1333–41.